Author： Kornick C.A. Santiago-Palma J. Moryl N. Payne R. Obbens E.A.M.T.
Publisher： Adis International
ISSN： 0114-5916
Source： Drug Safety, Vol.26, Iss.13, 2003-01, pp. : 951-973
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Benefit-Risk Assessment of Ropivacaine in the Management of Postoperative Pain
By Wolfgang Zink Bernhard M. Graf
Drug Safety, Vol. 27, Iss. 14, 2004-01 ,pp. :
Access to resources
Recommend
Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. :
Benefit-Risk Assessment of Levetiracetam in the Treatment of Partial Seizures
Drug Safety, Vol. 28, Iss. 10, 2005-01 ,pp. :
Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
By Mikuls T.R.
Drug Safety, Vol. 26, Iss. 1, 2003-01 ,pp. :
Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis
By Schmidt H. Woodcock B.G. Geisslinger G.
Drug Safety, Vol. 27, Iss. 3, 2004-01 ,pp. :